Comparing the current results to its competitors, Novavax Inc reported Revenue decrease in the 1 quarter 2026 year on year by -79.07 %, despite the revenue increase by the most of its competitors of 7.38 %, recorded in the same quarter.
Novavax inc , slower than the average decrease reported by the company's competitors of -95.13 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -95.13 %
Novavax Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment with several competitors possessing greater resources and experience, which may affect its commercial opportunities. Competitors are developing new products and updated versions of existing products, often incorporating adjuvants to enhance immunogenicity. Several competitors are also working on seasonal influenza vaccines using various technologies, including mRNA technology. Notably, Moderna and Pfizer are identified as key competitors in this area. Moderna is developing a COVID-19-influenza combination vaccine candidate and is engaged with the U.S. FDA for regulatory approval and commercialization. The company's competitive position is influenced by factors such as product efficacy, safety, reliability, availability, pricing, patent status, development speed, clinical trial outcomes, regulatory approvals, manufacturing capabilities, and the ability to attract qualified personnel and secure capital.
Provectus Biopharmaceuticals Inc's business model involves the development and commercialization of innovative therapies in the biopharmaceutical industry.
Ocugen Inc's business model is focused on the development and commercialization of innovative gene therapies to treat rare and underserved ocular diseases, with a particular emphasis on underserved patient populations. They aim to leverage their expertise in gene therapy and partnerships to advance novel treatments and bring them to market, ultimately improving the lives of patients in need.
Nkarta Inc is a biotechnology company with a business model centered on developing and commercializing engineered natural killer (NK) cell therapies for cancer patients. By utilizing proprietary technologies and expertise in genetic engineering, the company aims to enhance the therapeutic potential of NK cells and address unmet needs in the field of oncology. Nkarta Inc focuses on research, development, and production of these advanced cell therapies, collaborating with partners and regulators to bring innovative treatments to patients.
Nkgen Biotech Inc is a biotechnology company that focuses on developing and commercializing innovative cell therapies for the treatment of various diseases. Their business model involves conducting extensive research to identify and isolate specific cells capable of addressing medical conditions, followed by developing manufacturing processes to produce these cells in large quantities. They aim to partner with healthcare providers and pharmaceutical companies to ensure the effective distribution and delivery of their therapies to patients in need.
Sources:
Novavax inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Novavax inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
